- Conditions
- Malignant Gastric Outlet Obstruction
- Interventions
- Roux-en-Y Bypass, gastrojejunostomy
- Procedure
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
- Interventions
- Exercise, Calls and Newsletter
- Behavioral · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
- Interventions
- NX-1207
- Drug
- Lead sponsor
- Nymox Corporation
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 17
- States / cities
- Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Interventions
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Drug
- Lead sponsor
- Cogentus Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 247
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
- Conditions
- Advanced Cancer, Various, NOS
- Interventions
- BMS-833923, Lenalidomide, Dexamethasone, Bortezomib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
- Interventions
- Normoxia (with controlled re-oxygenation), Standard of care ventilation
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Up to 29 Days
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Bladder Outlet Obstruction
- Interventions
- Toviaz (Fesoterodine)
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 40 Years to 99 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Emesis
- Interventions
- ad lib feedings after pyloromyotomy, FLAP diet after pyloromyotomy
- Other
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 1 Day to 3 Months
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Swallowing Disorders, Achalasia, Outlet Obstruction, Gastric, Diffuse Esophageal Spasm
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
- Interventions
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Drug
- Lead sponsor
- Patrick C. Johnson, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- NX-1207
- Drug
- Lead sponsor
- Nymox Corporation
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 192 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Atherton, California • San Diego, California + 25 more
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Bone, CNS-Spinal CD/MEMBR, NOS, Lymph Nodes, Soft Tissue
- Interventions
- IGIMRT using a single dose of 24 Gy, IGIMRT 27 Gy in 3 fractions
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Gastric Outlet Obstruction
- Interventions
- AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG, High-grade Astrocytoma NOS, CNS Primary Tumor, NOS (Malignant Glioma)
- Interventions
- INCB7839
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
- Conditions
- Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
- Interventions
- solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 17
- States / cities
- Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
- Conditions
- Prostate Cancer, Post-Brachytherapy Bladder Outlet Obstruction
- Interventions
- Memokath 028SW Urethral Stent
- Device
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm, Nerve Sheath Neoplasms, Nerve Sheath Tumor, Nos, Solid Tumor, Adult, Solid Carcinoma
- Interventions
- [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)-Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
- Interventions
- Disposable device, Digital device, Clinic flow measurement
- Device
- Lead sponsor
- Wellspect HealthCare
- Industry
- Eligibility
- 45 Years to 85 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Thoracic Outlet Syndrome
- Interventions
- Ropivacaine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- B Cell Lymphoma, NHL, Adult, Mantle Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, HGBL With MYC and BCL2 and/or BCL6 Rearrangements, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Large B-cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, Non-hodgkin Lymphoma,B Cell, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Epstein-Barr Virus Positive DLBCL, Nos, Follicular Lymphoma Grade 3B, DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation, High Grade B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma Grade 3, Marginal Zone Splenic Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinaemia
- Interventions
- SynKIR-310
- Biological
- Lead sponsor
- Verismo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Atlanta, Georgia • Fairway, Kansas + 2 more
- Conditions
- Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter, Bloodstream Infection Due to Hickman Catheter
- Interventions
- Ethanol, Heparin Lock, Normal Saline
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Gastro-Intestinal Cancer
- Interventions
- 5-FU, Leucovorin, Irinotecan, Brivanib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Dallas, Texas • Temple, Texas
- Conditions
- Rheumatoid Arthritis, NOS
- Interventions
- BMS-582949, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Palm Desert, California • Santa Monica, California • Las Vegas, Nevada + 5 more
- Conditions
- Achalasia, Gastric Outlet Obstruction, Gastroparesis, GERD, Reflux, Fistula, Benign Neoplasm
- Interventions
- Endoscopic Surgery
- Procedure
- Lead sponsor
- Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey